Long‐term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single‐institutional experience with 1225 cases
- 16 July 2019
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (4) , 794-802
Abstract
Background and Objectives: To review long‐term survival outcomes of patients with Peritoneal metastasis (PM) who underwent colorectal cancer (CRS) and intraperitoneal chemotherapy (PIC).Methods: Patients that underwent CRS, with or without PIC, from January 1996 to March 2018 at the Peritonectomy Unit of St. George Hospital, Sydney were retrospectively analyzed from a prospectively maintained database.Results: The study comprised of 1225 cases, including 687 females (56.1%) and 538 males (43.9%). Diagnoses included CRC (n = 363), followed by HAMN (n = 317), LAMN (n = 297), mesothelioma (n = 101), ovarian cancer (n = 55), and others including gastric, sarcoma, and neuroendocrine tumor (n = 92). The median OS, 5‐ and 10‐year survivals for CRC were 35 months, 33% and 8%, respectively. Patients with LAMN, in relative to HAMN, experienced a higher median OS, 5‐ and 10‐year survivals (248 months vs 63 months; 82% vs 52% and 59% vs 28%). The median OS for mesothelioma was 60 months with 5‐ and 10‐year survivals of 48% and 19%, respectively. In ovarian cancer, the median OS was 30 months with 5‐ and 10‐year survivals of 26% and 10%, respectively. For the remaining histological diagnoses, median OS and 5‐year survival were 28 months and 27%, respectively.Conclusion: Our large‐cohort data showed that CRS/PIC can provide long‐term survival benefit to patients with PM of gastrointestinal and ovarian origin.Keywords
This publication has 24 references indexed in Scilit:
- Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2012
- Multidimensional Analysis of the Learning Curve for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Surface MalignanciesAnnals of Surgery, 2012
- Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosisCancer, 2010
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?Annals of Surgery, 2009
- Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal CarcinomatosisAnnals of Surgery, 2008
- Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy—A Journey to Becoming a Nationally Funded Peritonectomy CenterAnnals of Surgical Oncology, 2007
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Peritonectomy ProceduresAnnals of Surgery, 1995